

10/589420

IAP11 Rec'd PCT/PTO 15 AUG 2006

**English Translation of Claim Amendments Under PCT Article 19 and
explanation as filed**

Explanations according to Article 19(1) of PCT (Patent Cooperation Treaty)

Claim 1 is the same as claim 10 of the claims at application.

Claim 2 is a newly added claim according to claim 1, wherein the anti NC1 monoclonal antibody to be used in claim 1 is specified.

Claim 3 is a specification, wherein the immunological reaction according to claim 1 of the claims at application is restricted.

Claim 4 is a newly added claim according to claim 3, wherein the immunological reaction is restricted.

Claim 5 is an amendment and restriction of claim 4 of the claims at application.

Claim 6 is the same as claim 5 of the claims at application.

Claim 7 is the same as claim 6 of the claims at application.

Claim 8 is an amendment and restriction of claim 7 of the claims at application.

Claim 9 is the same as claim 8 of the claims at application.

Any claim above meets to the present invention sufficiently detailed and supported in the specification.

The anti NC1 monoclonal antibody referred in the literatures (Ref.1 and 2) by international search, stains normal kidney, but the anti NC1 monoclonal antibody of the present invention does not stain normal kidney but stains only nephritis kidney. The present invention dedicates the staining method and the anti NC1 monoclonal antibody described above.

The anti NC1 monoclonal antibody referred in the literatures (Ref.1 and 2) differs completely from the anti NC1 monoclonal antibody of the present invention described in the claims above in originating antigens, originating animal species of antibody, method for antibody preparation etc.

Furthermore, the referred literatures (Ref.3 and 4) do not have any description or any suggestion on the practical application as the anti NC1 monoclonal antibody detailed and specified in the claims of the present invention above.

- End -

Claims

1. (Amended) An immunohistofluorescent stain method using an anti NC1 monoclonal antibody in order to stain only kidneys of animal nephritis model and/or human nephritis but not stain normal kidneys.
2. (Amended) An anti NC1 monoclonal antibody characterized by staining kidneys of animal nephritis model and/or human nephritis but not staining normal kidneys.
3. (Amended) The anti NC1 monoclonal antibody characterized by immunological reaction using type IV collagen NC1 domain or its peptide (hereinafter referred to as NC1) extracted from human and/or animal renal glomeruli and both ELISA method and Western blot method.
4. (Amended) The anti NC1 monoclonal antibody characterized by reacting with NC1 extracted from human and/or animal renal glomeruli using both ELISA method and Western blot method, and further characterized by staining only kidneys of nephritis but not staining normal kidneys as immune reaction using immunohistofluorescent stain method.
5. (Amended) An immunologically detecting method to detect NC1 in the live specimens, wherein the anti NC1 monoclonal antibody according to claim 5 is used for detection of nephritis.
6. (Amended) An anti NC1 antibody remover
7. (Amended) A NC1 remover
8. (Amended) A type IV collagen assay kit, wherein it consists of an anti type IV collagen antibody prepared using the renal type IV collagen as the antigen which is used for purification of the NC1 monoclonal antibody as claimed in claim 3.
9. (Amended) An administration method, wherein it consists of higher booster dose compared to the initial dose in cases of booster administration in order to prepare an antibody and/or to vaccination.
10. (Deleted)